Novartis Transfers Vaccines Technology To Biological E
BMI Core View: Corporate social responsibility is an underappreciated business activity in the pharmaceutical industry. Like all commercial entities, drugmakers are fully entitled to focus on the generation of profits and shareholder value. However, recent bad publicity - such as product recalls, inappropriate pricing in developing countries and dangerous production processes - means that pharmaceutical companies are increasingly accountable to employees, governments, the environment and, most importantly, patients. Firms that do not embrace CSR will lose investors and underperform compared with their rivals.
Novartis has entered into a development and licensing agreement with India-based Biological E for two vaccines to protect against typhoid and paratyphoid fevers. According to the Switzerland-headquartered multinational, the agreement helps the firm to 'deliver accessible and affordable vaccines that address unmet medical need in endemic regions'. The involvement of Novartis in this area of corporate social responsibility follows the launch of the Global Health Innovative Technology Fund in April 2013. This fund is Japan's first public-private partnership to develop new treatments to fight infections diseases in the developing world. Key partners include: Japan Ministry of Foreign Affairs and Japan Ministry of Health, Labour and Welfare, Astellas, Daiichi Sankyo, Eisai, Shionogi, Takeda, the Bill and Melinda Gates Foundation and the UN Development Programme.
Prevalence Of Typhoid And Paratyphoid Fever
|Poor Drinking-Water Sources|
|Total Unimproved Drinking Water Sources As A Percentage Of Total Population In Selected Countries (LHS) And Low Per-Capita Pharmaceutical Spending (RHS)|